When was LEO Pharma founded?

LEO Pharma was founded in 1908 and raised its 1st funding round 101 years after it was founded.

Where is LEO Pharma located?

LEO Pharma is headquartered in Copenhagen, Denmark.

Who is the current CEO of LEO Pharma?

Christophe Bourdon of LEO Pharma.

How many employees does LEO Pharma have?

As of May 31, 2025, LEO Pharma has 142 employees, reflecting a 374% year-over-year growth in headcount.

Is LEO Pharma a funded company?

LEO Pharma is a funded company, having raised a total of $560M across 3 funding rounds to date. The company's 1st funding round was a $***** Unattributed round, raised on Oct 12, 2009.

When was the latest funding round of LEO Pharma?

LEO Pharma's latest funding was a $***** PE round on Mar 31, 2022, with participation from 0 investor.

What is the annual revenue of LEO Pharma?

Annual revenue of LEO Pharma is between ₹100 Cr and ₹500 Cr as on Mar 31, 2025

Where does LEO Pharma rank among its competitors?

LEO Pharma ranks 6th amongst 2560 active competitors, of which 871 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of LEO Pharma?

LEO Pharma's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Immuneel secured the most recent funding round in June, 2026.

LEO Pharma - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of drugs for treating dermatology diseases. It offers variety of medicines such as topical creams and ointments, oral tablets, and injectable biologics for the treatment of psoriasis, eczema, and rare diseases. The pipeline products include Tralokinumab for atopic dermatitis and Delgocitinib a topical pan-JAK inhibitor for chronic hand eczema.

Website: www.leo-pharma.com/
Social

Key Metrics

Founded Year

1908

Location

Copenhagen, Denmark

Stage

Late Stage

Total Funding

$560M in 3 rounds

Latest Funding Round

PE, Mar 31, 2022, $*****

Investors

Nordic Capital

Ranked

6^th among 2560 active competitors

Annual Revenue

₹100 - ₹500 Cr as on Mar 31, 2025

Employee Count

142 as on May 31, 2025

Investment & Acquisitions

Replay & 6 more

Similar Companies

Evommune & 163 more

View LEO Pharma's full profile

LEO Pharma is associated with 11 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Leo Medical Care s.r.o. CIN: 02517141 , Czech Republic, Active	Jan 07, 2014	-	-
LEO Holding A/S CIN: 39122251 , Denmark, Active		-	4 (As on Dec 31, 2021)
LEO FONDET CIN: 11623336 , Denmark, Active	Aug 19, 1984	-	-
Leo Pharma CIN: 0404.780.604 , Belgium, Active	Apr 01, 1967	-	28 (As on Dec 31, 2023)	-
PHARMAWORLD Holding, a.s. CIN: 60737395 , Czech Republic, Active	Jan 18, 1995	-	-
Leo Pharma A / S CIN: 56759514 , Denmark, Active	Feb 09, 1962	-	5804 (As on Dec 31, 2021)
LEO PHARMA, INC. CIN: 800485929 , United States, Active	Dec 31, 1999	-	235 (As on Dec 31, 2024)	-
NeoLeo.eu s.r.o. CIN: 44740352 , Czech Republic, Active	Dec 09, 1991	-	-
Leo holdings s.r.o. CIN: 27413691 , Czech Republic, Active	Jan 04, 2006	-	-
LEO Ventures A/S CIN: 41600004 , Denmark, Deadpooled	Aug 12, 2020	-	-
LEO PHARMA DISTRIBUTORS PRIVATE LIMITED CIN: U63020KL2012PTC032178 , India, Active	Sep 17, 2012	₹100 - ₹500 Cr (As on Mar 31, 2025)	188 (As on Apr 01, 2026)

LEO Pharma has raised a total funding of $560M over 3 rounds. Its first funding round was on Oct 12, 2009. LEO Pharma has 1 institutional investor.

Here is the list of recent funding rounds of LEO Pharma:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 31, 2022	8032851	PE	2010668	5732860	5089838	7159686
Mar 23, 2021	1827848	PE	8665819	9669908	1534159	6045118
Oct 12, 2009	4003952	Unattributed	8230400	3395593	9353995	3982611

Access funding benchmarks and valuations. Sign up today!

View details of LEO Pharma's funding rounds and investors

Here are the details of LEO Pharma's key team members:

Christophe Bourdon: CEO of LEO Pharma.

LEO Pharma's Board of Directors

LEO Pharma's board has 27 active members. Jukka Pekka Pertola, Christophe Dominique Luc Charles Bourdon, Paul Olivier Marie Navarre, Signe Maria Christensen, Lena Elisabeth Svanberg, Philip Eickhoff and Lars Green are part of team and Per Schmidt, Johannes Gerardus Christiaan Petrus Schikan, Jesper Brandgaard, Gorm Milan Thamsborg, Peter Haahr, Ann Berit Sveigaard, Lotte Gossmann, Vilhelm Johannes Kahlke, Franck Mareno, lawyer Morten Drewes Pedersen, Hanne Ann-Dorthe Ginderskov, Patrick O'Sullivan, Judith Blankholm, Jonas Agnblad, Karin Attermann, Ann Berit Moestrup, Jørgen Halsteen, Erling Finn Juhl Nielsen, Jesper Mailind and Niels Smidt Rastrup Andersen are independent board members.

Here is the list of LEO Pharma's board of directors:

Name	Type	Representing	Status	Duration
Jukka Pekka Pertola	Team	-	Current	5y 3m
qqbtuse	Team	-	Past	7y 3m
fhwvlcx	Team	-	Current	3y 4m
gxbf{ik	Team	-	Current	4y 9m
dgwtqst	Team	-	Current	4y 5m
kyntaqm	Team	-	Current	9y 2m
kblbrll	Team	-	Current	6y 9m
ipu{cyn	Team	-	Past	2y 1m
Per Schmidt	Independent board member	-	Current	12y 3m
qsxteov	Independent board member	-	Current	4y 6m
kkjgete	Independent board member	-	Current	4y 5m
xxcjmyt	Independent board member	-	Current	3y 9m
qwiniai	Independent board member	-	Current	3y 9m
cffhhag	Independent board member	-	Current	4y 9m
tndkbfk	Independent board member	-	Current	8y 2m
bbklvwj	Independent board member	-	Current	2y 5m
aeikioi	Independent board member	-	Current	6y 9m
ipejsan	Independent board member	-	Current	4y 6m
ojootir	Independent board member	-	Current	7y 7m
kaxyear	Independent board member	-	Current	4y 2m
flqpvnw	Independent board member	-	Current	9y 8m
ydpwseo	Independent board member	-	Current	2y 4m
vvxmyco	Independent board member	-	Current	3y 6m
fgge{py	Independent board member	-	Current	7y 1m
flbcz{i	Independent board member	-	Current	5y 9m
psxictm	Independent board member	-	Current	7y 6m
qwgwgya	Independent board member	-	Current	2y 7m
{rgucwi	Independent board member	-	Past	5y 4m
jjub{mr	Independent board member	-	Past	5y 8m
skmtkyx	Independent board member	-	Past	5y 5m
luucguf	Independent board member	-	Past	7y 2m
ffysbez	Independent board member	-	Past	1y 7m
{ywbbra	Independent board member	-	Past	4y 3m
baxjbfz	Independent board member	-	Past	2y 7m
yiebfcy	Independent board member	-	Past	9y 3m
pvwjvir	Independent board member	-	Past	7y 3m
rci{ner	Independent board member	-	Past	2y 1m
chqeowj	Independent board member	-	Past	6y 3m
qgaugvy	Independent board member	-	Past	4y 3m
omcoxep	Independent board member	-	Past	6y 5m
pivqfgh	Independent board member	-	Past	3y 7m
xzvkecy	Independent board member	-	Past	5y 6m
hioamjf	Independent board member	-	Past	4y 4m
m{vkmiu	Independent board member	-	Past	5y 8m
kdzjjd{	Independent board member	-	Past	1y 6m
uzvjvqo	Independent board member	-	Past	1y 8m
oaez{pq	Independent board member	-	Past	8y 3m
jwopeyh	Independent board member	-	Past	1y 6m
nnsxssq	Independent board member	-	Past	8y 3m
sglzoix	Independent board member	-	Past	7y 7m
ibxwcgy	Independent board member	-	Past	3y 3m
wbqwwvk	Independent board member	-	Past	4y 6m
emfcydb	Independent board member	-	Past	7y 2m
myajedw	Independent board member	-	Past	9y 2m
zgvhzbp	Independent board member	-	Past	5y 8m
soiglmp	Independent board member	-	Past	3y 2m
wflugrz	Independent board member	-	Past	4y 5m
mlht{uq	Independent board member	-	Past	5y 2m
fzujegt	Independent board member	-	Past	7y 2m
wgmrngu	Independent board member	-	Past	2y 9m
rsuhicp	Independent board member	-	Past	3y 6m
aprszko	Independent board member	-	Past	3y 1m
fhs{vfz	Independent board member	-	Past	5y 5m
se{phfm	Independent board member	-	Past	9y 1m
zbguuqr	Independent board member	-	Past	1y 7m
deamfpe	Independent board member	-	Past	8y 8m
gsqqm{t	Independent board member	-	Past	9y 2m
sedfqps	Independent board member	-	Past	6y 3m
wzzpmmx	Independent board member	-	Past	6y 7m
pnazdcv	Independent board member	-	Past	3y 3m

View details of LEO Pharma's Founder profiles and Board Members

LEO Pharma's employee count trend

LEO Pharma has 142 employees as of May 25. The total employee count is 373.0% more than what it was in May 24. Here is LEO Pharma's employee count trend over the years:

Uncover LEO Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of LEO Pharma include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of LEO Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 17 others	75/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, SV Health Investors & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	LEO Pharma 1908, Copenhagen (Denmark), Late Stage	Developer of drugs for treating dermatology diseases	$560M	Nordic Capital	71/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
8th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, Khosla Ventures & 23 others	71/100
10th	Zymeworks 2003, Vancouver (Canada), Public	Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer	$146M	CTI Life Sciences Fund, Advanced Biotechnologies Venture Fund ... & 17 others	71/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on LEO Pharma's competitors? Click here to see the top ones

LEO Pharma has made 4 investments in companies including PellePharm and SkinVision. LEO Pharma has also acquired 3 companies including Replay and Timber Pharmaceuticals.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Apr 30, 2026	Acquisition	Replay	2021	San Diego (United States)
Aug 21, 2023	Acquisition	Timber Pharmaceuticals	2011	Woodcliff Lake (United States)
Nov 22, 2018	Investments	PellePharm	2012	Menlo Park (United States)